Sundar PichaiSundar Pichai earned $164M in 2023

Jason Lettmann is the CEO of ALX Oncology Holdings Inc., a biotech company focused on developing cancer treatments. He has a solid educational background with a B.A. in Psychology from the University of Iowa and an M.B.A. from the University...

Quick Links
A

Jason Lettmann

CEO of ALX Oncology Holdings Inc.

Education

B.A. in Psychology from the University of Iowa and an M.B.A. from the University of Michigan's Ross School of Business

Field of Expertise

Business & Management

Sector of Economy

Healthcare

CEO of ALX Oncology Holdings Inc. for

1 year 9 months (Sep 2023 - Present)

Previous Experience

Partner at Morgenthaler Ventures, former CEO of Promedior Inc.

Rivals

Competitors/colleagues of Jason Lettmann

Holdings

See how much did Jason Lettmann make over time.

Jason Lettmann's insider trading history shows he has been actively involved in his company's stock. Notably, in 2020, he made trades with values reaching close to $19 million in December. His holdings have fluctuated significantly, highlighting a strong confidence in...

Loading...

Total Stock Sold

$12.24M

ALXO

$12.24M

473,173 ALXO shares

What if they kept their stock?

If Jason Lettmann didn't sell their stock, today they would have:
Extra ALXO473,173 shares worth $14.20M.
This is 16.01% and $1.96M more than what they got when they sold the stock.

Insider Trading

See recent insider trades of Jason Lettmann.

ALXO

42,000 shares

ALXO

Mar 14, 2025

Received

ALXO

$2.48K

ALXO at $1.15/share

Feb 19, 2025

Sale

ALXO

$49.77K

ALXO at $11.31/share

Mar 14, 2024

Purchase

ALXO

60,000 shares

ALXO

Feb 14, 2024

Received

ALXO

$9.08M

ALXO at $27.91/share

Dec 13, 2021

Sale

ALXO

$4.69M

ALXO at $32.17/share

Dec 8, 2021

Sale

ALXO

$7.60M

ALXO at $19.00/share

Jul 21, 2020

Purchase

Compensation History

See how much did Jason Lettmann make over time.

In 2023, Jason Lettmann's total compensation package at ALX Oncology Holdings amounted to $487,183. This includes a base salary of $217,330 and a performance-based bonus of $119,003, nearly 55% of his salary. This pay structure is designed to incentivize him towards achieving the company's corporate goals. Lettmann's compensation package reflects his role in navigating ALX through the competitive biotech landscape. Notably, he also received $151,290 in other compensation which included fees for prior board service and an annual non-employee director award. Despite the sizeable bonuses and potential stock option grants, no stock has vested for him as of 2023, showing a long-term perspective on performance. Such compensation not only aims to attract and retain top talent but also aligns his interests with those of shareholders, building a promising outlook for the company.

Year

2023

Total Compensation

$487.62K

Salary

$217.33K

Board Justification

The compensation program is designed to attract, engage, and retain executive officers while aligning their interests with those of stockholders through performance-based incentives.

Bonus

$119.00K

Board Justification

The annual target bonus for Mr. Lettmann was set at 55% of his annual base salary, prorated based on the number of days in 2023 during which he served as CEO.

Other

$151.29K

Board Justification

Includes $35,071 for board and committee service prior to his appointment as CEO and $116,219 for the non-employee director annual option award in June 2023.

Restricted Stock

$0.00(0 RSU)

Board Justification

No stock was reported as vested in 2023 for Mr. Lettmann.

Performance Metrics

The performance metrics for Mr. Lettmann's bonus were based entirely on corporate goals.

Other ALX Oncology Holdings Inc. CEOs

Here are other CEOs of ALX Oncology Holdings Inc.